Significant Growth Expected for Stem Cell Manufacturing Market
The market outlook has proven favorable for regenerative medicines as well as genetically modified Cell Therapy products. The role of stem cells has grown vastly; various stem cell lines are being evaluated by life science researchers for use in effective disease management and biological studies. This trend has provided a lucrative growth opportunity for cell line manufacturers offering specific stem cell lines and related products.
This has been underscored in a research study published by MarketsandMarkets that expects the global stem cell manufacturing market to reach a value of USD 18.0 billion by 2026 at a CAGR of ~9.4% from 2021.
Stem cell manufacturing involves various cell isolation & bioprocessing technologies utilized for the production scale-up of stem cell lines while retaining their reproducibility and potency. Current advancements in the stem cell manufacturing industry include accelerated stem cell production and process automation to achieve the desired economies of scale. Stem cell lines, derived from human or animal sources, are the most important element of a stem cell manufacturing process and further utilized for clinical and research applications. Finished stem cell lines are often offered by manufacturers along with culture media and incubators to maintain cell viability and potency.
The stem cell industry is also witnessing significant public-private funding and investments. This has driven the development of innovative technologies for efficient manufacturing scale-up, effective quality control, and greater product affordability. Evolving regulatory frameworks across major markets will ensure the greater use of stem cell products, thereby supporting the expansion of the stem cell manufacturing industry during the next decade.
As of 2021, prominent companies in Stem cell manufacturing market include Thermo Fisher Scientific (US), Merck Milliopore (Germany), Lonza Group AG (Switzerland), Danaher Corporation (US) and Sartorius AG (Germany), among others.
- In January 2021, Thermo Fisher Scientific acquired Henogen S.A., Novasep's viral vector manufacturing business, to strengthen its capabilities for cell and gene vaccines and therapies globally.
- In November 2020, Lonza Group AG signed an agreement with FUJIFILM Cellular Dynamics. Under the agreement, Lonza granted FUJIFILM Cellular Dynamics expanded use of its non-exclusive license to its innovative Nucleofector technology. Likewise, FUJIFILM Cellular Dynamics granted Lonza a non-exclusive right to use its patents related to iPSC generation. This will accelerate the development and manufacture of cell therapies.
- In March 2020, Danaher acquired the Biopharma business from General Electric Company’s Life Sciences division and renamed it Cytiva.
- In October 2019, Thermo Fisher Scientific launched Gibco BenchStable Media, which remains stable at room temperature and reduces reliance on cold storage.
To read more about the market study and the assumptions considered, download the PDF Brochure